Article | February 26, 2020

Ensuring An Unbiased Comparator Arm In Clinical Development

Source: Cytel
Clinical Trial Transparency: The Technology Imperative

Regulators in both the United States and Europe have responded positively to the use of SCAs in clinical development. While implementation of this method for regulatory purposes might be a new development, the majority of statistical and mathematical theories used for the design of SCAs are decades old and familiar to the scientific community. The desire to speed up and lower the cost of drug development, coupled with increased availability of rich real-world data, contributed to the increased openness towards using SCAs as supplementary evidence to accompany regulatory submissions using single arm trial data only.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: